321 related articles for article (PubMed ID: 32077253)
21. Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial.
Dunst J; Jürgens H; Sauer R; Pape H; Paulussen M; Winkelmann W; Rübe C
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):919-30. PubMed ID: 7607966
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study.
Obata H; Ueda T; Kawai A; Ishii T; Ozaki T; Abe S; Tanaka K; Tsuchiya H; Matsumine A; Yabe H;
Cancer; 2007 Feb; 109(4):767-75. PubMed ID: 17238190
[TBL] [Abstract][Full Text] [Related]
23. Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France.
Corvest V; Marec-Bérard P; Lervat C; Pacquement H; Toulmonde M; Gentet JC; Laurence V; Cleirec M; Mansuy L; Bompas E; Castex MP; Taque S; Filhon B; Tabone MD; Verité C; Entz-Werle N; Saumet L; Guimard G; Pondrom M; Chevreau C; Flandrin J; Duranteau L; Rousset-Jablonski C; Brugières L; Jimenez M; Le Deley MC; Gaspar N; Fresneau B
Int J Cancer; 2023 Apr; 152(8):1659-1667. PubMed ID: 36250317
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies.
Bacci G; Picci P; Ferrari S; Mercuri M; Brach del Prever A; Rosito P; Barbieri E; Tienghi A; Forni C
Cancer; 1998 Mar; 82(6):1174-83. PubMed ID: 9506366
[TBL] [Abstract][Full Text] [Related]
25. Definitive surgery and multiagent systemic therapy for patients with localized Ewing sarcoma family of tumors: local outcome and prognostic factors.
Krasin MJ; Davidoff AM; Rodriguez-Galindo C; Billups CA; Fuller CE; Neel MD; Merchant TE
Cancer; 2005 Jul; 104(2):367-73. PubMed ID: 15948159
[TBL] [Abstract][Full Text] [Related]
26. No advantages in the addition of ifosfamide and VP-16 to the standard four-drug regimen in the maintenance phase of neoadjuvant chemotherapy of Ewing's sarcoma of bone: results of two sequential studies.
Bacci G; Picci P; Ruggieri P; Ferrari S; Mercuri M; Fabbri N; Rosito P; Barbieri E; Ferraro A; Casadei R
J Chemother; 1993 Aug; 5(4):247-57. PubMed ID: 8229153
[TBL] [Abstract][Full Text] [Related]
27. Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.
Tural D; Molinas Mandel N; Dervisoglu S; Oner Dincbas F; Koca S; Colpan Oksuz D; Kantarci F; Turna H; Selcukbiricik F; Hiz M
Jpn J Clin Oncol; 2012 May; 42(5):420-6. PubMed ID: 22416252
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study.
Ahrens S; Hoffmann C; Jabar S; Braun-Munzinger G; Paulussen M; Dunst J; Rübe C; Winkelmann W; Heinecke A; Göbel U; Winkler K; Harms D; Treuner J; Jürgens H
Med Pediatr Oncol; 1999 Mar; 32(3):186-95. PubMed ID: 10064186
[TBL] [Abstract][Full Text] [Related]
29. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
[TBL] [Abstract][Full Text] [Related]
30. Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma.
Paulino AC; Nguyen TX; Mai WY; Teh BS; Wen BC
Pediatr Blood Cancer; 2007 Aug; 49(2):145-8. PubMed ID: 16732580
[TBL] [Abstract][Full Text] [Related]
31. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group.
Donaldson SS; Torrey M; Link MP; Glicksman A; Gilula L; Laurie F; Manning J; Neff J; Reinus W; Thompson E; Shuster JJ
Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):125-35. PubMed ID: 9747829
[TBL] [Abstract][Full Text] [Related]
32. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
[TBL] [Abstract][Full Text] [Related]
33. Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience.
Zhang J; Huang Y; Sun Y; He A; Zhou Y; Hu H; Yao Y; Shen Z
BMC Cancer; 2019 Dec; 19(1):1168. PubMed ID: 31791278
[TBL] [Abstract][Full Text] [Related]
34. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
Miser JS; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Grier HE
J Clin Oncol; 2004 Jul; 22(14):2873-6. PubMed ID: 15254055
[TBL] [Abstract][Full Text] [Related]
35. Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors.
Krasin MJ; Rodriguez-Galindo C; Billups CA; Davidoff AM; Neel MD; Merchant TE; Kun LE
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):830-8. PubMed ID: 15465200
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcome of patients with recurrent or refractory localized Ewing's sarcoma family of tumors: A retrospective report from the Japan Ewing Sarcoma Study Group.
Umeda K; Miyamura T; Yamada K; Sano H; Hosono A; Sumi M; Okita H; Kumamoto T; Kawai A; Hirayama J; Jyoko R; Sawada A; Nakayama H; Hosoya Y; Maeda N; Yamamoto N; Imai C; Hasegawa D; Chin M; Ozaki T;
Cancer Rep (Hoboken); 2021 Jun; 4(3):e1329. PubMed ID: 33452866
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of extraskeletal vs. skeletal Ewing sarcoma patients treated with standard chemotherapy protocol.
Salah S; Abuhijla F; Ismail T; Yaser S; Sultan I; Halalsheh H; Shehadeh A; Abdelal S; Almousa A; Jaber O; Abu-Hijlih R
Clin Transl Oncol; 2020 Jun; 22(6):878-883. PubMed ID: 31429039
[TBL] [Abstract][Full Text] [Related]
38. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
[TBL] [Abstract][Full Text] [Related]
39. Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.
Dunst J; Ahrens S; Paulussen M; Rübe C; Winkelmann W; Zoubek A; Harms D; Jürgens H
Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):379-84. PubMed ID: 9788419
[TBL] [Abstract][Full Text] [Related]
40. Validation of a multi-modal treatment protocol for Ewing sarcoma--a report from the polish pediatric oncology group.
Raciborska A; Bilska K; Drabko K; Chaber R; Sobol G; Pogorzała M; Wyrobek E; Połczyńska K; Rogowska E; Rodriguez-Galindo C; Wożniak W
Pediatr Blood Cancer; 2014 Dec; 61(12):2170-4. PubMed ID: 25163763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
